2 weeks ago
Biogen (BIIB) and AbbVie (ABBV) Receive Rare Double Upgrades: What Investors Need to Know
Wolfe Research upgrades Biogen and AbbVie to Outperform, setting $300 targets based on pipeline strength, patent extensions, and solid earnings performance.
The post Biogen (BIIB) and AbbVie (ABBV) Receive Rare Double Upgrades: What Investors Need to Know appeared first on Blockonomi.
Source: Blockonomi →Related News
- 29 minutes ago
Market Recap: Bitcoin Hovers Below $80K as Nvidia (NVDA) Stock Rallies 9% on Ear...
- 43 minutes ago
Ripple Prime Expands Into Traditional Finance With Delta One Trading Desk
- 1 hour ago
UAE Royal Family Invests in Trump-Linked World Liberty Trust Company Amid OCC Ap...
- 1 hour ago
Bitcoin (BTC) Surges Past $80K as Nvidia Earnings Exceed Expectations
- 12 hours ago
The Trade Desk, Inc. (TTD) Stock: New Zuma Platform Brings Smarter AI, Simpler M...